-
From Access to Eligibility: What Poland’s Real-World Stage III NSCLC Data Reveal About Treatment Pathways and Health Policy
Add ILCN as a preferred sourceDr. Łukasz Kuncman expands on findings from a multicenter Polish study analyzing referral patterns and clinical practice in patients with unresectable stage III NSCLC, emphasizing that access to the modern standard of care depends on a chain of eligibility.
More Recent News
-
HARMONi-6 Trial Results Show Consistent OS Benefit Across Key Subgroups
Dr. Shun Lu, who presented the findings during the main plenary session at the 2026 ASCO Annual Meeting, said the results support adopting ivonescimab plus chemotherapy as a potential new standard of care for advanced squamous NSCLC.
-
Asandeutertinib Goes Head-to-Head With Osimertinib in Phase II ESAONA Trial
Interim results from the ESAONA trial, presented by Dr. Yuankai Shi, revealed that asandeutertinib demonstrated significant improvements in iORR and iPFS versus osimertinib for EGFR-mutant NSCLC with brain metastases.